Cormorant Asset Management’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Cormorant Asset Management’s Portfolio EIDX Stock Details EIDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-993,185	Closed	-$50.2M	–	115
2020 Q3	$50.2M	Sell	993,185 -62,117	-6%	-$2.79M	1.93%	19
2020 Q2	$50.3M	Sell	1,055,302 -44,698	-4%	-$2.08M	1.92%	20
2020 Q1	$53.9M	Buy	1,100,000 +604,308	+122%	+$30.8M	2.5%	13
2019 Q4	$28.4M	Sell	495,692 -44,994	-8%	-$2.23M	1.14%	32
2019 Q3	$19.4M	Sell	540,686 -11,235	-2%	-$439K	1.18%	30
2019 Q2	$17.2M	Buy	551,921 +44,357	+9%	+$1.2M	0.99%	33
2019 Q1	$11.9M	Buy	507,564 +121,718	+32%	+$1.95M	0.8%	38
2018 Q4	$5.31M	Hold	385,846	–	–	0.43%	45
2018 Q3	$3.85M	Hold	385,846	–	–	0.25%	52
2018 Q2	$7.46M	Buy	+385,846	New	+$8.09M	0.55%	43

Other funds holding EIDX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Cormorant Asset Management's EIDX Position: Q4 2020 in Review

Cormorant Asset Management sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q4 2020, closing a stake of 993,185 shares — an estimated $50.2M sold.

Cormorant Asset Management first reported a position in EIDX in Q2 2018 and held it in 10 quarters. The position peaked at $53.9M in Q1 2020. 121 funds tracked by Wall St. Rank hold EIDX as of Q4 2020.

Cormorant Asset Management reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
Cormorant Asset Management sold 993,185 Eidos Therapeutics, Inc. Common Stock shares in Q4 2020, an estimated $50.2M.
Cormorant Asset Management first reported a position in Eidos Therapeutics, Inc. Common Stock in Q2 2018 and held it in 10 quarters.
Cormorant Asset Management's Eidos Therapeutics, Inc. Common Stock position peaked at $53.9M in Q1 2020.
121 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q4 2020.

Based on Cormorant Asset Management's 13F filing for Q4 2020, filed 16 Feb 2021.